

Resource Summary Report

Generated by [dkNET](#) on Aug 20, 2026

GIST48

RRID:CVCL_7041

Type: Cell Line

Proper Citation

RRID:CVCL_7041

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_7041

Proper Citation: RRID:CVCL_7041

Description: Cell line GIST48 is a Cancer cell line with a species of origin Homo sapiens (Human)

Disease: Gastrointestinal stromal tumor

Defining Citation: [PMID:16954519](#), [PMID:16982758](#), [PMID:19706776](#), [PMID:22294416](#), [PMID:22665524](#), [PMID:29866822](#), [PMID:30488756](#)

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: GIST48

Synonyms: GIST-48, GIST 48

Cross References: cancercellines:CVCL_7041, ChEMBL-Cells:ChEMBL4513107, ChEMBL-Targets:ChEMBL4513125, Cosmic:1180673, Cosmic:1873950, GEO:GSM486229, GEO:GSM2527252, GEO:GSM2527253, GEO:GSM2786737, Progenetix:CVCL_7041, PubChem_Cell_line:CVCL_7041, Wikidata:Q54835858

ID: CVCL_7041

Record Creation Time: 20220427T215902+0000

Record Last Update: 20260815T232841+0000

Ratings and Alerts

No rating or validation information has been found for GIST48.

No alerts have been found for GIST48.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Wang CC, et al. (2026) Urokinase Plasminogen Activator Receptor-Associated Protein (uPARAP) as a Potential Next Generation Molecular Target for Treatment of Gastrointestinal Stromal Tumors (GIST). International journal of cancer, 159(3), 797.

Ravegnini G, et al. (2026) Identification of MBT3T as a new effective therapeutic option in imatinib-resistant gastrointestinal stromal tumors (GISTs). Journal of experimental & clinical cancer research : CR, 45(1).

Hemming ML, et al. (2022) MOZ and Menin-MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor. Cancer discovery, 12(7), 1804.

Hemming ML, et al. (2019) Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer research, 79(5), 994.

Smith BD, et al. (2019) Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer cell, 35(5), 738.